正川股份(603976) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥134,081,892.26, a decrease of 9.98% compared to the same period last year[4] - The total profit for the quarter was ¥1,546,641.29, reflecting a significant decline of 80.83% year-over-year[4] - The net profit attributable to shareholders was ¥2,251,002.92, down 70.23% from the previous year[4] - The net profit after deducting non-recurring gains and losses for the quarter was -¥55,800.75, a decrease of 100.77% compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.02, a decline of 60.00% year-over-year[5] - The company experienced a 70.85% decrease in total profit for the year-to-date period, totaling ¥17,029,719.73[4] - Total operating revenue for the first three quarters of 2025 was RMB 457.75 million, a decrease of 25% compared to RMB 609.66 million in the same period of 2024[17] - Net profit for the first three quarters of 2025 was RMB 16.34 million, a decline of 68.6% compared to RMB 51.94 million in 2024[18] - Operating profit for the first three quarters of 2025 was RMB 17.07 million, a decrease of 72% from RMB 60.86 million in 2024[17] - Basic earnings per share for the first three quarters of 2025 were RMB 0.11, compared to RMB 0.34 in the same period of 2024[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,891,506,649.32, a decrease of 3.34% from the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to RMB 1,891,506,649.32, a decrease from RMB 1,956,811,650.01 as of December 31, 2024[13] - The company's total liabilities decreased to RMB 688,884,142.36 from RMB 733,404,723.33, reflecting a decline of approximately 6.1%[15] - Total current liabilities decreased to RMB 221,494,277.82 from RMB 270,080,438.76, a reduction of about 18%[15] - The equity attributable to shareholders decreased to RMB 1,202,622,506.96 from RMB 1,223,406,926.68, a decrease of about 1.7%[15] - The non-current assets totaled RMB 1,014,587,035.51, down from RMB 1,080,952,079.64, indicating a decrease of about 6.1%[14] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥105,822,452.35, an increase of 20.92%[4] - Cash flow from operating activities for the first three quarters of 2025 was RMB 105.82 million, an increase of 20.9% compared to RMB 87.52 million in 2024[20] - Cash flow from investing activities for the first three quarters of 2025 was negative RMB 16.82 million, a significant decline from positive RMB 147.35 million in 2024[21] - Cash and cash equivalents at the end of the first three quarters of 2025 totaled RMB 120.65 million, down from RMB 311.24 million at the end of 2024[21] - The company's cash and cash equivalents increased to RMB 140,079,429.34 from RMB 108,902,577.00, reflecting a growth of approximately 28.5%[13] Inventory and Receivables - Accounts receivable rose to RMB 163,535,744.01, up from RMB 148,208,950.23, indicating an increase of about 10.3%[13] - Inventory levels increased to RMB 258,864,827.79 from RMB 250,483,335.27, representing a growth of approximately 3.4%[13] - The company reported a significant increase in prepayments, which rose to RMB 8,118,126.14 from RMB 2,509,823.19, marking an increase of approximately 224%[13] Market Conditions - The company attributed the decline in profits to intensified competition in the pharmaceutical market and fluctuations in downstream customer demand[8] Tax and Other Expenses - The company reported a tax expense of RMB 690,422.36 for the first three quarters of 2025, a significant decrease from RMB 6.47 million in 2024[18] - The company did not report any net profit from subsidiaries under common control for the periods in question[19] - The company has no significant changes in the shareholding structure or related party transactions during the reporting period[12]